Interferon (IFN)-related DNA damage resistant signature (IRDS) genes are a subgroup of interferon-stimulated genes (ISGs) found upregulated in different cancer types, which promotes resistance to DNA damaging chemotherapy and radiotherapy. Along with briefly discussing IFNs and signalling in this review, we highlighted how different IRDS genes are affected by viruses. On the contrary, different strategies adopted to suppress a set of IRDS genes (STAT1, IRF7, OAS family, and BST2) to induce (chemo- and radiotherapy) sensitivity were deliberated. Significant biological pathways that comprise these genes were classified, along with their frequently associated genes (IFIT1/3, IFITM1, IRF7, ISG15, MX1/2 and OAS1/3/L). Major upstream regulators from the IRDS genes were identified, and different IFN types regulating these genes were outlined. Functional interfaces of IRDS proteins with DNA/RNA/ATP/GTP/NADP biomolecules featured a well-defined pharmacophore model for STAT1/IRF7-dsDNA and OAS1/OAS3/IFIH1-dsRNA complexes, as well as for the genes binding to GDP or NADP+. The Lys amino acid was found commonly interacting with the ATP phosphate group from OAS1/EIF2AK2/IFIH1 genes. Considering the premise that targeting IRDS genes mediated resistance offers an efficient strategy to resensitize tumour cells and enhances the outcome of anti-cancer treatment, this review can add some novel insights to the field.

Department of Medical Biosciences Building 6M Umeå University 901 85 Umeå Sweden

Inserm UMRS1131 Institut de Génétique Moléculaire Université Paris 7 Hôpital St Louis F 75010 Paris France

Institute of Genetics and Molecular Medicine University of Edinburgh Edinburgh EH4 2XR UK

International Centre for Cancer Vaccine Science University of Gdansk ul Kładki 24 80 822 Gdansk Poland

RECAMO Masaryk Memorial Cancer Institute Zlutykopec 7 65653 Brno Czech Republic

See more in PubMed

Deng L., Liang H., Fu S., Weichselbaum R.R., Fu Y.X. From DNA damage to nucleic acid sensing: A strategy to enhanceradiation therapy. Clin. Cancer Res. 2016;22:20–25. doi: 10.1158/1078-0432.CCR-14-3110. PubMed DOI

Burnette B.C., Liang H., Lee Y., Chlewicki L., Khodarev N.N., Weichselbaum R.R., Fu Y.X., Auh S.L. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 2011;71:2488–2496. doi: 10.1158/0008-5472.CAN-10-2820. PubMed DOI PMC

Lim J.Y., Gerber S.A., Murphy S.P., Lord E.M. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol. Immunother. 2014;63:259–271. doi: 10.1007/s00262-013-1506-7. PubMed DOI PMC

Sarhan J., Liu B.C., Muendlein H.I., Weindel C.G., Smirnova I., Tang A.Y., Ilyukha V., Sorokin M., Buzdin A., Fitzgerald K.A., et al. Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. Cell Death Differ. 2019;26:332–347. doi: 10.1038/s41418-018-0122-7. PubMed DOI PMC

Snyder A.G., Hubbard N.W., Messmer M.N., Kofman S.B., Hagan C.E., Orozco S.L., Chiang K., Daniels B.P., Baker D., Oberst A. Intra tumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci. Immunol. 2019;4:eaaw2004. doi: 10.1126/sciimmunol.aaw2004. PubMed DOI PMC

Erdal E., Haider S., Rehwinkel J., Harris A.L., McHugh P.J. A prosurvival DNA damage-induced cytoplasmic interferon responseis mediated by end resection factors and is limited by Trex1. Genes Dev. 2017;31:353–369. doi: 10.1101/gad.289769.116. PubMed DOI PMC

Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The Protein DataBank. Nucleic Acids Res. 2000;28:235–242. doi: 10.1093/nar/28.1.235. PubMed DOI PMC

Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 1957;147:258–267. PubMed

Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005;5:375–386. doi: 10.1038/nri1604. PubMed DOI

Kotredes K.P., Gamero A.M. Interferons as inducers of apoptosis in malignant cells. J. Interferon Cytokine Res. 2013;33:162–170. doi: 10.1089/jir.2012.0110. PubMed DOI PMC

Gresser I., Maury C., Brouty-Boyé D. Mechanism of the antitumou reffect of interferon in mice. Nature. 1972;239:167–168. doi: 10.1038/239167a0. PubMed DOI

Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D. Demonstration of an interferon dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA. 1998;95:7556–7561. doi: 10.1073/pnas.95.13.7556. PubMed DOI PMC

Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., Stark G.R. Interferons at age 50: Past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 2007;6:975–990. doi: 10.1038/nrd2422. PubMed DOI PMC

Walter M.R. The role of structure in the biology of interferon signaling. Front. Immunol. 2020;11:606489. doi: 10.3389/fimmu.2020.606489. PubMed DOI PMC

Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014;14:36–49. doi: 10.1038/nri3581. PubMed DOI PMC

Staeheli P. Interferon induced proteins and the antiviral state. Adv. Virus Res. 1990;38:147–200. PubMed

Thomas C., Moraga I., Levin D., Krutzik P.O., Podoplelova Y., Trejo A., Lee C., Yarden G., Vleck S.E., Glenn J.S., et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 2011;146:621–632. doi: 10.1016/j.cell.2011.06.048. PubMed DOI PMC

Mendoza J.L., Escalante N.K., Jude K.M., SotolongoBellon J., Su L., Horton T.M., Tsutsumi N., Berardinelli S.J., Haltiwanger R.S., Piehler J., et al. Structure of the IFNγ receptor complex guides design of biased agonists. Nature. 2019;567:56–60. doi: 10.1038/s41586-019-0988-7. PubMed DOI PMC

Mendoza J.L., Schneider W.M., Hoffmann H.H., Vercauteren K., Jude K.M., Xiong A., Moraga I., Horton T.M., Glenn J.S., De Jong Y.P., et al. The IFN-λ-IFN-λR1-IL-10Rβ Complex reveals structural features underlying type III IFN functional plasticity. Immunity. 2017;46:379–392. doi: 10.1016/j.immuni.2017.02.017. PubMed DOI PMC

Mesev E.V., LeDesma R.A., Ploss A. Decoding type I and III interferon signalling during viral infection. Nat. Microbiol. 2019;4:914–924. doi: 10.1038/s41564-019-0421-x. PubMed DOI PMC

Oon S., Wilson N.J., Wicks I. Targeted therapeutics in SLE: Emerging strategies to modulate the interferon pathway. Clin. Transl. Immunol. 2016;5:e79. doi: 10.1038/cti.2016.26. PubMed DOI PMC

Krause C.D., Pestka S. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol. Ther. 2005;106:299–346. doi: 10.1016/j.pharmthera.2004.12.002. PubMed DOI

Novick D., Cohen B., Rubinstein M. The human interferon alpha/beta receptor: Characterization and molecular cloning. Cell. 1994;77:391–400. doi: 10.1016/0092-8674(94)90154-6. PubMed DOI

Roisman L.C., Jaitin D.A., Baker D.P., Schreiber G. Mutational analysis of the IFNAR1 binding site on IFN alpha 2 reveals the architecture of a weak ligand-receptor binding site. J. Mol. Biol. 2005;353:271–281. doi: 10.1016/j.jmb.2005.08.042. PubMed DOI

Jaitin D.A., Roisman L.C., Jaks E., Gavutis M., Piehler J., Vander Heyden J., Uze G., Schreiber G. Inquiring into the differential action of interferons (IFNs): An IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol. Cell Biol. 2006;26:1888–1897. doi: 10.1128/MCB.26.5.1888-1897.2006. PubMed DOI PMC

Piehler J., Schreiber G. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2. J. Mol. Biol. 1999;294:223–237. doi: 10.1006/jmbi.1999.3230. PubMed DOI

Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 1998;67:227–264. doi: 10.1146/annurev.biochem.67.1.227. PubMed DOI

Hamilton J.A., Whitty G.A., Kola I., Hertzog P.J. Endogenous IFN-alpha beta suppresses colony-stimulating factor(CSF) 1 stimulated macrophage DNA synthesis and mediates inhibitory effects of lipopolysaccharide and TNF-alpha. J. Immunol. 1996;156:2553–2557. PubMed

Marié I., Durbin J.E., Levy D.E. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J. 1998;17:6660–6669. doi: 10.1093/emboj/17.22.6660. PubMed DOI PMC

Vogel S.N., Fertsch D. Endogenous interferon production by endotoxin-responsive macrophages provides an autostimulatory differentiation signal. Infect. Immun. 1984;45:417–423. doi: 10.1128/IAI.45.2.417-423.1984. PubMed DOI PMC

Takaoka A., Mitani Y., Suemori H., Sato M., Yokochi T., Noguchi S., Tanaka N., Taniguchi T. Crosstalk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science. 2000;288:2357–2360. doi: 10.1126/science.288.5475.2357. PubMed DOI

Foster G.R., Rodrigues O., Ghouze F., Schulte-Frohlinde E., Testa D., Liao M.J., Stark G.R., Leadbeater L., Thomas H.C. Different relative activities of human cell derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J. Interferon Cytokine Res. 1996;16:1027–1033. doi: 10.1089/jir.1996.16.1027. PubMed DOI

Hibbert L., Foster G.R. Human type I interferons differ greatly in their effects on the proliferation of primary B cells. J. Interferon Cytokine Res. 1999;19:309–318. doi: 10.1089/107999099314009. PubMed DOI

Sadler A.J., Williams B.R. Interferon inducible antiviral effectors. Nat. Rev. Immunol. 2008;8:559–568. doi: 10.1038/nri2314. PubMed DOI PMC

Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., Vitale I., Goubar A., Baracco E.E., Remédios C., et al. Cancer cell autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 2014;20:1301–1309. doi: 10.1038/nm.3708. PubMed DOI

Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., Li X.D., Mauceri H., Beckett M., Darga T., et al. STING-dependent cytosolic DNA sensing promotes radiation induced Type I interferon dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843–852. doi: 10.1016/j.immuni.2014.10.019. PubMed DOI PMC

Yang H., Wang H., Ren J., Chen Q., Chen Z.J. cGAS is essential for cellular senescence. Proc. Natl. Acad. Sci. USA. 2017;114:E4612–E4620. doi: 10.1073/pnas.1705499114. PubMed DOI PMC

Gasser S., Zhang W.Y.L., Tan N.Y.J., Tripathi S., Suter M.A., Chew Z.H., Khatoo M., Ngeow J., Cheung F.S.G. Sensing of dangerous DNA. Mech. Ageing Dev. 2017;165:33–46. doi: 10.1016/j.mad.2016.09.001. PubMed DOI

Hong C., Tijhuis A.E., Foijer F. The cGAS Paradox: Contrasting roles for cGAS-STING pathway in chromosomal instability. Cells. 2019;8:1228. doi: 10.3390/cells8101228. PubMed DOI PMC

Nastasi C., Mannarino L., D’Incalci M. DNA damage response and immune defense. Int. J. Mol. Sci. 2020;21:7504. doi: 10.3390/ijms21207504. PubMed DOI PMC

Jiang M., Chen P., Wang L., Li W., Chen B., Liu Y., Wang H., Zhao S., Ye L., He Y., et al. cGAS-STING, an important pathway in cancer immunotherapy. J. Hematol. Oncol. 2020;13:81. doi: 10.1186/s13045-020-00916-z. PubMed DOI PMC

Luecke S., Holleufer A., Christensen M.H., Jønsson K.L., Boni G.A., Sørensen L.K., Johannsen M., Jakobsen M.R., Hartmann R., Paludan S.R. cGAS is activated by DNA in a length-dependent manner. EMBO Rep. 2017;18:1707–1715. doi: 10.15252/embr.201744017. PubMed DOI PMC

Marcus A., Mao A.J., Lensink-Vasan M., Wang L., Vance R.E., Raulet D.H. Tumor derived cGAMP triggers a STING mediated interferon response in non-tumor cells to activate the NK cell response. Immunity. 2018;49:754–763.e4. doi: 10.1016/j.immuni.2018.09.016. PubMed DOI PMC

Kanda N., Shimizu T., Tada Y., Watanabe S. IL-18 enhances IFN-γ induced production of CXCL9, CXCL10, and CXCL11 in humank eratinocytes. Eur. J. Immunol. 2007;37:338–350. doi: 10.1002/eji.200636420. PubMed DOI

Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer. 2009;9:798–809. doi: 10.1038/nrc2734. PubMed DOI PMC

Jones L.M., Broz M.L., Ranger J.J., Ozcelik J., Ahn R., Zuo D., Ursini-Siegel J., Hallett M.T., Krummel M., Muller W.J. STAT3 Establishes an immuno suppressive micro environment during the early stages of breast carcinogenes is to promote tumor growth and metastasis. Cancer Res. 2016;76:1416–1428. doi: 10.1158/0008-5472.CAN-15-2770. PubMed DOI PMC

Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mulé J., Kerr W.G., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multi component antitumor immunity. Nat. Med. 2005;11:1314–1321. doi: 10.1038/nm1325. PubMed DOI

Grégoire C., Chasson L., Luci C., Tomasello E., Geissmann F., Vivier E., Walzer T. The trafficking of natural killer cells. Immunol. Rev. 2007;220:169–182. doi: 10.1111/j.1600-065X.2007.00563.x. PubMed DOI PMC

Elsea C.R., Roberts D.A., Druker B.J., Wood L.J. Inhibition of p38MAPK suppresses inflammatory cytokine induction by Etoposide, 5-Fluorouracil, and Doxorubicin without affecting tumoricidal activity. PLoS ONE. 2008;3:e02355. doi: 10.1371/journal.pone.0002355. PubMed DOI PMC

Li A., Yi M., Qin S., Song Y., Chu Q., Wu K. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J. Hematol. Oncol. 2019;12:35. doi: 10.1186/s13045-019-0721-x. PubMed DOI PMC

Parkes E.E., Walker S.M., Taggart L.E., McCabe N., Knight L.A., Wilkinson R., McCloskey K.D., Buckley N.E., Savage K.I., Salto-Tellez M., et al. Activation of STING-dependent innate immune signaling by S-Phase specific DNA damage in breast cancer. J. Natl. Cancer Inst. 2017;109:djw199. doi: 10.1093/jnci/djw199. PubMed DOI PMC

Harding S.M., Benci J.L., Irianto J., Discher D.E., Minn A.J., Greenberg R.A. Mitotic progression following DNA damage enables pattern recognition within micro nuclei. Nature. 2017;548:466–470. doi: 10.1038/nature23470. PubMed DOI PMC

Gerber S.A., Sedlacek A.L., Cron K.R., Murphy S.P., Frelinger J.G., Lord E.M. IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor. Am. J. Pathol. 2013;182:2345–2354. doi: 10.1016/j.ajpath.2013.02.041. PubMed DOI PMC

Tanimoto T., Yamamoto S., Taniai M., Taniguchi M., Ariyasu H., Ushio C., Aga M., Mukai Y., Tsutsumi Y., Ariyasu T., et al. The combination of IFN-alpha 2 and IFN-alpha 8 exhibits synergistic antiproliferative activity on renal cell carcinoma (RCC) cell lines through increased binding affinity for IFNAR-2. J. Interferon Cytokine Res. 2007;27:517–523. doi: 10.1089/jir.2007.0155. PubMed DOI

DiFranco S., Turdo A., Todaro M., Stassi G. Role of Type I and II Interferons in colorectal cancer and melanoma. Front. Immunol. 2017;8:878. doi: 10.3389/fimmu.2017.00878. PubMed DOI PMC

Minn A.J. Interferons and the immunogenic effects of cancer therapy. Trends Immunol. 2015;36:725–737. doi: 10.1016/j.it.2015.09.007. PubMed DOI PMC

Khodarev N.N., Beckett M., Labay E., Darga T., Roizman B., Weichselbaum R.R. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc. Natl. Acad. Sci. USA. 2004;101:1714–1719. doi: 10.1073/pnas.0308102100. PubMed DOI PMC

Harris A.L. Hypoxia- a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2002;2:38–47. doi: 10.1038/nrc704. PubMed DOI

Hallahan D.E., Haimovitz-Friedman A., Kufe D.W., Fuks Z., Weichselbaum R.R. The role of cytokines in radiation oncology. Important Adv. Oncol. 1993:71–80. PubMed

Marples B., Scott S.D., Hendry J.H., Embleton M.J., Lashford L.S., Margison G.P. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther. 2000;7:511–517. doi: 10.1038/sj.gt.3301116. PubMed DOI

Kita K., Sugaya S., Zhai L., Wu Y.P., Wano C., Chigira S., Nomura J., Takahashi S., Ichinose M., Suzuki N. Involvement of LEU13 in interferon-induced refractoriness of human RSa cells to cell killing by Xrays. Radiat. Res. 2003;160:302–308. doi: 10.1667/RR3039. PubMed DOI

Benci J.L., Johnson L.R., Choa R., Xu Y., Qiu J., Zhou Z., Xu B., Ye D., Nathanson K.L., June C.H., et al. Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune check point blockade. Cell. 2019;178:933–948.e14. doi: 10.1016/j.cell.2019.07.019. PubMed DOI PMC

Duarte C.W., Willey C.D., Zhi D., Cui X., Harris J.J., Vaughan L.K., Mehta T., McCubrey R.O., Khodarev N.N., Weichselbaum R.R., et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS ONE. 2012;7:e029653. doi: 10.1371/journal.pone.0029653. PubMed DOI PMC

Tsai M.H., Cook J.A., Chandramouli G.V., DeGraff W., Yan H., Zhao S., Coleman C.N., Mitchell J.B., Chuang E.Y. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res. 2007;67:3845–3852. doi: 10.1158/0008-5472.CAN-06-4250. PubMed DOI

Liauw S.L., Connell P.P., Weichselbaum R.R. New paradigms and future challenges in radiation oncology: An update of biological targets and technology. Sci. Transl. Med. 2013;5:173sr2. doi: 10.1126/scitranslmed.3005148. PubMed DOI PMC

Khodarev N.N., Minn A.J., Efimova E.V., Darga T.E., Labay E., Beckett M., Mauceri H.J., Roizman B., Weichselbaum R.R. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res. 2007;67:9214–9220. doi: 10.1158/0008-5472.CAN-07-1019. PubMed DOI

Cheon H., Stark G.R. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc. Natl. Acad. Sci. USA. 2009;106:9373–9378. doi: 10.1073/pnas.0903487106. PubMed DOI PMC

Cheon H., Yang J., Stark G.R. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J. Interferon Cytokine Res. 2011;31:33–40. doi: 10.1089/jir.2010.0100. PubMed DOI PMC

Cheon H., Holvey-Bates E.G., Schoggins J.W., Forster S., Hertzog P., Imanaka N., Rice C.M., Jackson M.W., Junk D.J., Stark G.R. IFNβ dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 2013;32:2751–2763. doi: 10.1038/emboj.2013.203. PubMed DOI PMC

Khodarev N.N., Roach P., Pitroda S.P., Golden D.W., Bhayani M., Shao M.Y., Darga T.E., Beveridge M.G., Sood R.F., Sutton H.G., et al. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS ONE. 2009;4:e05821. doi: 10.1371/journal.pone.0005821. PubMed DOI PMC

Khodarev N.N., Roizman B., Weichselbaum R.R. Molecular pathways: Interferon/stat1 pathway: Role in the tumor resistance to genotoxic stress and aggressive growth. Clin. Cancer Res. 2012;18:3015–3021. doi: 10.1158/1078-0432.CCR-11-3225. PubMed DOI

Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–820. doi: 10.1016/j.cell.2010.01.022. PubMed DOI

Mackenzie K.J., Carroll P., Martin C.A., Murina O., Fluteau A., Simpson D.J., Olova N., Sutcliffe H., Rainger J.K., Leitch A., et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461–465. doi: 10.1038/nature23449. PubMed DOI PMC

Cheon H., Borden E.C., Stark G.R. Interferons and their stimulated genes in the tumor microenvironment. Semin. Oncol. 2014;41:156–173. doi: 10.1053/j.seminoncol.2014.02.002. PubMed DOI PMC

Weichselbaum R.R., Ishwaran H., Yoon T., Nuyten D.S., Baker S.W., Khodarev N., Su A.W., Shaikh A.Y., Roach P., Kreike B., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. USA. 2008;105:18490–18495. doi: 10.1073/pnas.0809242105. PubMed DOI PMC

Wallace T.A., Martin D.N., Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: Examining the evidence on a national and global scale. Carcinogenesis. 2011;32:1107–1121. doi: 10.1093/carcin/bgr066. PubMed DOI PMC

UniProt Consortium UniProt: A worldwide hub of protein knowledge. Nucleic Acids Res. 2019;47:D506–D515. doi: 10.1093/nar/gky1049. PubMed DOI PMC

Raudvere U., Kolberg L., Kuzmin I., Arak T., Adler P., Peterson H., Vilo J. g:Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update) Nucleic Acids Res. 2019;47:W191–W198. doi: 10.1093/nar/gkz369. PubMed DOI PMC

Reimand J., Isserlin R., Voisin V., Kucera M., Tannus-Lopes C., Rostamianfar A., Wadi L., Meyer M., Wong J., Xu C., et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and Enrichment Map. Nat. Protoc. 2019;14:482–517. doi: 10.1038/s41596-018-0103-9. PubMed DOI PMC

Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., Amin N., Schwikowski B., Ideker T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–2504. doi: 10.1101/gr.1239303. PubMed DOI PMC

Rusinova I., Forster S., Yu S., Kannan A., Masse M., Cumming H., Chapman R., Hertzog P.J. Interferome v2.0: An updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2013;41:D1040–D1046. doi: 10.1093/nar/gks1215. PubMed DOI PMC

Stark G.R., Darnell J.E. The JAK-STAT pathway at twenty. Immunity. 2012;36:503–514. doi: 10.1016/j.immuni.2012.03.013. PubMed DOI PMC

Savoldi-Barbosa M., Sakamoto-Hojo E.T. Influence of interferon-gamma on radiation-induced apoptosis in normal and a taxia-telangiectasia fibroblast cell lines. Teratog. Carcinog. Mutagen. 2001;21:417–429. doi: 10.1002/tcm.1029. PubMed DOI

Sirota N.P., Bezlepkin V.G., Kuznetsova E.A., Lomayeva M.G., Milonova I.N., Ravin V.K., Gaziev A.I., Bradbury R.J. Modifying effect in vivo of interferon alpha on induction and repair of lesions of DNA of lymphoid cells of gamma-irradiated mice. Radiat. Res. 1996;146:100–105. doi: 10.2307/3579402. PubMed DOI

Wu B., Hur S. How RIG-I like receptors activate MAVS. Curr. Opin. Virol. 2015;12:91–98. doi: 10.1016/j.coviro.2015.04.004. PubMed DOI PMC

Boelens M.C., Wu T.J., Nabet B.Y., Xu B., Qiu Y., Yoon T., Azzam D.J., Twyman-SaintVictor C., Wiemann B.Z., Ishwaran H., et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 2014;159:499–513. doi: 10.1016/j.cell.2014.09.051. PubMed DOI PMC

Gonzalez K.J., Moncada-Giraldo D.M., Gutierrez J.B. In silico identification of potential inhibitors against human 2′-5′-oligoadenylate synthetase (OAS) proteins. Comput. Biol. Chem. 2020;85:107211. doi: 10.1016/j.compbiolchem.2020.107211. PubMed DOI

Souissi I., Ladam P., Cognet J.A., LeCoquil S., Varin-Blank N., Baran-Marszak F., Metelev V., Fagard R. A STAT3-inhibitory hairpin decoy oligodeoxy nucleotide discriminates between STAT1 and STAT3 and induces death in a human colon carcinoma cell line. Mol. Cancer. 2012;11:12. doi: 10.1186/1476-4598-11-12. PubMed DOI PMC

Joo C.H., Shin Y.C., Gack M., Wu L., Levy D., Jung J.U. Inhibition of interferon regulatory factor7 (IRF7) mediated interferon signal transduction by the Kaposi’s sarcoma-associated herpes virus viral IRF homolog vIRF3. J. Virol. 2007;81:8282–8292. doi: 10.1128/JVI.00235-07. PubMed DOI PMC

Kalathiya U., Padariya M., Faktor J., Coyaud E., Alfaro J.A., Fahraeus R., Hupp T.R., Goodlett D.R. Interfaces with structure dynamics of the workhorses from cells revealed through cross-linking mass spectrometry (CLMS) Biomolecules. 2021;11:382. doi: 10.3390/biom11030382. PubMed DOI PMC

Chen X., Vinkemeier U., Zhao Y., Jeruzalmi D., Darnell J.E., Jr., Kuriyan J. Crystal structure of atyrosine phosphorylated STAT-1 dimer bound to DNA. Cell. 1998;93:827–839. doi: 10.1016/S0092-8674(00)81443-9. PubMed DOI

Ibsen M.S., Gad H.H., Andersen L.L., Hornung V., Julkunen I., Sarkar S.N., Hartmann R. Structural and functional analysis reveals that human OASL binds dsRNA to enhance RIG-I signaling. Nucleic Acids Res. 2015;43:5236–5248. doi: 10.1093/nar/gkv389. PubMed DOI PMC

Panne D., Maniatis T., Harrison S.C. An atomic model of the interferon-beta enhanceosome. Cell. 2007;129:1111–1123. doi: 10.1016/j.cell.2007.05.019. PubMed DOI PMC

Dar A.C., Dever T.E., Sicheri F. Higher-order substrate recognition of eIF2 alpha by the RNA-dependent protein kinase PKR. Cell. 2005;122:887–900. doi: 10.1016/j.cell.2005.06.044. PubMed DOI

Chen M.H., Ben-Efraim I., Mitrousis G., Walker-Kopp N., Sims P.J., Cingolani G. Phospholipid scramblase 1 contains a nonclassical nuclear localization signal with unique binding site in importin alpha. J. Biol. Chem. 2005;280:10599–10606. doi: 10.1074/jbc.M413194200. PubMed DOI

Wu B., Peisley A., Richards C., Yao H., Zeng X., Lin C., Chu F., Walz T., Hur S. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5. Cell. 2013;152:276–289. doi: 10.1016/j.cell.2012.11.048. PubMed DOI

Yang H., Wang J., Jia X., McNatt M.W., Zang T., Pan B., Meng W., Wang H.W., Bieniasz P.D., Xiong Y. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc. Natl. Acad. Sci. USA. 2010;107:18428–18432. doi: 10.1073/pnas.1011485107. PubMed DOI PMC

Abbas Y.M., Laudenbach B.T., Martínez-Montero S., Cencic R., Habjan M., Pichlmair A., Damha M.J., Pelletier J., Nagar B. Structure of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing N1 and N2 ribose 2′-Omethylations. Proc. Natl. Acad. Sci. USA. 2017;114:E2106–E2115. doi: 10.1073/pnas.1612444114. PubMed DOI PMC

Donovan J., Whitney G., Rath S., Korennykh A. Structural mechanism of sensing long dsRNA via an oncatalytic domain in human oligoadenylate synthetase 3. Proc. Natl. Acad. Sci. USA. 2015;112:3949–3954. doi: 10.1073/pnas.1419409112. PubMed DOI PMC

Donovan J., Dufner M., Korennykh A. Structural basis for cytosolic double-stranded RNA surveillance by human oligoadenylate synthetase 1. Proc. Natl. Acad. Sci. USA. 2013;110:1652–1657. doi: 10.1073/pnas.1218528110. PubMed DOI PMC

Rennie M.L., McKelvie S.A., Bulloch E.M., Kingston R.L. Transient dimerization of human MxA promotes GTP hydrolysis, resulting in a mechanical power stroke. Structure. 2014;22:1433–1445. doi: 10.1016/j.str.2014.08.015. PubMed DOI

Fribourgh J.L., Nguyen H.C., Matreyek K.A., Alvarez F.J.D., Summers B.J., Dewdney T.G., Aiken C., Zhang P., Engelman A., Xiong Y. Structural insight into HIV-1 restriction by MxB. Cell Host Microbe. 2014;16:627–638. doi: 10.1016/j.chom.2014.09.021. PubMed DOI PMC

Mazza C. Ph.D. Thesis. Universite Joseph Fourier; Grenoble, France: 1997. Human Type I 17 Beta-Hydroxysteroid Dehydrogenase: Site Directed Mutagenesis and X-ray Crystallography Structure Function Analysis.

Wathelet M.G., Lin C.H., Parekh B.S., Ronco L.V., Howley P.M., Maniatis T. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol. Cell. 1998;1:507–518. doi: 10.1016/S1097-2765(00)80051-9. PubMed DOI

Yang H., Lin C.H., Ma G., Baffi M.O., Wathelet M.G. Interferon regulatory factor-7 synergizes with other transcription factors through multiple interactions with p300/CBP coactivators. J. Biol. Chem. 2003;278:15495–15504. doi: 10.1074/jbc.M212940200. PubMed DOI

Ning S., Pagano J.S., Barber G.N. IRF7: Activation, regulation, modification and function. Genes Immun. 2011;12:399–414. doi: 10.1038/gene.2011.21. PubMed DOI PMC

Lin R., Génin P., Mamane Y., Hiscott J. Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7. Mol. Cell Biol. 2000;20:6342–6353. doi: 10.1128/MCB.20.17.6342-6353.2000. PubMed DOI PMC

Kileng O., Bergan V., Workenhe S.T., Robertsen B. Structural and functional studies of an IRF-7-like gene from Atlantics almon. Dev. Comp. Immunol. 2009;33:18–27. doi: 10.1016/j.dci.2008.07.020. PubMed DOI

Kristiansen H., Gad H.H., Eskildsen-Larsen S., Despres P., Hartmann R. The oligoadenylate synthetase family: An ancient protein family with multiple antiviral activities. J. Interferon Cytokine Res. 2011;31:41–47. doi: 10.1089/jir.2010.0107. PubMed DOI

Kristiansen H., Scherer C.A., McVean M., Iadonato S.P., Vends S., Thavachelvam K., Steffensen T.B., Horan K.A., Kuri T., Weber F., et al. Extracellular 2′-5′ oligoadenylate synthetase stimulates RNaseL-independent antiviral activity: A novel mechanism of virus induced innate immunity. J. Virol. 2010;84:11898–11904. doi: 10.1128/JVI.01003-10. PubMed DOI PMC

Latham K.E., Cosenza S., Reichenbach N.L., Mordechai E., Adelson M.E., Kon N., Horvath S.E., Charubala R., Mikhailov S.N., Pfeiderer W., et al. Inhibition of growth of estrogen receptor positive and estrogen receptor negative breast cancer cells in culture by AA-etherA, a stable 2-5A derivative. Oncogene. 1996;12:827–837. PubMed

Feng Z., Zheng W., Tang Q., Cheng L., Li H., Ni W., Pan X. Fludarabine inhibits STAT1-mediated up-regulation of caspase-3 expression indexamethasone-induced osteoblasts apoptosis and slows the progression of steroid induced a vascular necrosis of the femoral head in rats. Apoptosis. 2017;22:1001–1012. doi: 10.1007/s10495-017-1383-1. PubMed DOI

Gunning P.T., Katt W.P., Glenn M., Siddiquee K., Kim J.S., Jove R., Sebti S.M., Turkson J., Hamilton A.D. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: Structural recognition of STAT SH2 domains. Bioorg. Med. Chem. Lett. 2007;17:1875–1878. doi: 10.1016/j.bmcl.2007.01.077. PubMed DOI

Zhou X.X., Gao P.J., Sun B.G. Pravastatin attenuates interferon-gamma action via modulation of STAT1 to prevent aortic atherosclerosis in apolipoprotein E-knockout mice. Clin. Exp. Pharmacol. Physiol. 2009;36:373–379. doi: 10.1111/j.1440-1681.2008.05067.x. PubMed DOI

Böhmer F.D., Friedrich K. Protein tyrosine phosphatases as wardens of STAT signaling. JAKSTAT. 2014;3:e28087. doi: 10.4161/jkst.28087. PubMed DOI PMC

Porritt R.A., Hertzog P.J. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol. 2015;36:150–160. doi: 10.1016/j.it.2015.02.002. PubMed DOI

Rytinki M.M., Kaikkonen S., Pehkonen P., Jääskeläinen T., Palvimo J.J. PIA Sproteins: Pleiotropic interactors associated with SUMO. Cell. Mol. Lif eSci. 2009;66:3029–3041. doi: 10.1007/s00018-009-0061-z. PubMed DOI PMC

Usmani S.Z., Sexton R., Ailawadhi S., Shah J.J., Valent J., Rosenzweig M., Lipe B., Zonder J.A., Fredette S., Durie B., et al. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J. 2015;5:e334. doi: 10.1038/bcj.2015.62. PubMed DOI PMC

Lan Q., Peyvandi S., Duffey N., Huang Y.T., Barras D., Held W., Richard F., Delorenzi M., Sotiriou C., Desmedt C., et al. Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breastc ancer. Oncogene. 2019;38:2814–2829. doi: 10.1038/s41388-018-0624-2. PubMed DOI PMC

Liang Q., Fu B., Wu F., Li X., Yuan Y., Zhu F. ORF45 of Kaposi’s sarcoma-associated herpes virus inhibits phosphorylation of interferon regulatory factor 7 by IKKε and TBK1 as an alternatives ubstrate. J. Virol. 2012;86:10162–10172. doi: 10.1128/JVI.05224-11. PubMed DOI PMC

Jammi N.V., Whitby L.R., Beal P.A. Small molecule inhibitors of the RNA-dependent protein kinase. Biochem. Biophys. Res. Commun. 2003;308:50–57. doi: 10.1016/S0006-291X(03)01318-4. PubMed DOI

Sanfilippo C., Pinzone M.R., Cambria D., Longo A., Palumbo M., DiMarco R., Condorelli F., Nunnari G., Malaguarnera L., DiRosa M. OAS gene family expression is associated with HIV-Related neurocognitive disorders. Mol. Neurobiol. 2018;55:1905–1914. doi: 10.1007/s12035-017-0460-3. PubMed DOI

Field L.L., Bonnevie-Nielsen V., Pociot F., Lu S., Nielsen T.B., Beck-Nielsen H. OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Diabetes. 2005;54:1588–1591. doi: 10.2337/diabetes.54.5.1588. PubMed DOI

Banerjee S., Gusho E., Gaughan C., Dong B., Gu X., Holvey-Bates E., Talukdar M., Li Y., Weiss S.R., Sicheri F., et al. OAS-RNase L innate immune pathway mediates the cytotoxicity of a DNA-demethylating drug. Proc. Natl. Acad. Sci. USA. 2019;116:5071–5076. doi: 10.1073/pnas.1815071116. PubMed DOI PMC

Kodigepalli K.M., Bowers K., Sharp A., Nanjundan M. Roles and regulation of phospholipid scramblases. FEBS Lett. 2015;589:3–14. doi: 10.1016/j.febslet.2014.11.036. PubMed DOI

Tufail Y., Cook D., Fourgeaudm L., Powers C.J., Merten K., Clark C.L., Hoffman E., Ngo A., Sekiguchi K.J., O’Shea C.C., et al. Phosphatidyl serine exposure controls viral innate immune responses by microglia. Neuron. 2017;93:574–586.e8. doi: 10.1016/j.neuron.2016.12.021. PubMed DOI PMC

Chow K.T., Gale M., Jr., Loo Y.M. RIG-I and other RNA sensors in antiviral immunity. Annu. Rev. Immunol. 2018;36:667–694. doi: 10.1146/annurev-immunol-042617-053309. PubMed DOI

Kasumba D.M., Hajake T., Oh S.W., Kotenko S.V., Kato H., Fujita T. A Plant-derived nucleic acid reconciles type I IFN and a Pyroptotic-like event in immunity against respiratory viruses. J. Immunol. 2017;199:2460–2474. doi: 10.4049/jimmunol.1700523. PubMed DOI

Oberson A., Spagnuolo L., Puddinu V., Barchet W., Rittner K., Bourquin C. NAB2 is a novel immune stimulator of MDA-5 that promotes a strong type I interferon response. Oncotarget. 2017;9:5641–5651. doi: 10.18632/oncotarget.23725. PubMed DOI PMC

Johnson B., VanBlargan L.A., Xu W., White J.P., Shan C., Shi P.Y., Zhang R., Adhikari J., Gross M.L., Leung D.W., et al. Human IFIT3 modulates IFIT1 RNA binding specificity and protein stability. Immunity. 2018;48:487–499.e5. doi: 10.1016/j.immuni.2018.01.014. PubMed DOI PMC

Pidugu V.K., Wu M.M., Yen A.H., Pidugu H.B., Chang K.W., Liu C.J., Lee T.C. IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling. Oncogene. 2019;38:3232–3247. doi: 10.1038/s41388-018-0662-9. PubMed DOI

Mahauad-Fernandez W.D., Okeoma C.M. B49, a BST-2-based peptide, inhibits adhesion and growth of breast cancer cells. Sci. Rep. 2018;8:4305. doi: 10.1038/s41598-018-22364-z. PubMed DOI PMC

Cheng Y., Ma X.L., Wei Y.Q., Wei X.W. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim. Biophys. Acta Rev. Cancer. 2019;1871:289–312. doi: 10.1016/j.bbcan.2019.01.005. PubMed DOI

Chrétien I., Marcuz A., Courtet M., Katevuo K., Vainio O., Heath J.K., White S.J., DuPasquier L. CTX, a Xenopus thymocyte receptor, defines a molecular family conserved throughout vertebrates. Eur. J. Immunol. 1998;28:4094–4104. doi: 10.1002/(SICI)1521-4141(199812)28:12<4094::AID-IMMU4094>3.0.CO;2-2. PubMed DOI

Padariya M., Kalathiya U., Mikac S., Dziubek K., Tovar Fernandez M.C., Sroka E., Fahraeus R., Sznarkowska A. Viruses, cancer and non-self recognition. Open Biol. 2021;11:200348. doi: 10.1098/rsob.200348. PubMed DOI PMC

Villarreal L.P. The source of self: Genetic parasites and the origin of adaptive immunity. Ann. N. Y. Acad. Sci. 2009;1178:194–232. doi: 10.1111/j.1749-6632.2009.05020.x. PubMed DOI

Chuong E.B., Elde N.C., Feschotte C. Regulatory evolution of innate immunity through co-option of endogenous retroviruses. Science. 2016;351:1083–1087. doi: 10.1126/science.aad5497. PubMed DOI PMC

Didcock L., Young D.F., Goodbourn S., Randall R.E. The V protein of simianvirus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J. Virol. 1999;73:9928–9933. doi: 10.1128/JVI.73.12.9928-9933.1999. PubMed DOI PMC

Andrejeva J., Young D.F., Goodbourn S., Randall R.E. Degradation of STAT1 and STAT2 by the V proteins of simianvirus 5 and human parainfluenza virus type 2, respectively: Consequences for virus replication in the presence of alpha/beta and gamma interferons. J. Virol. 2002;76:2159–2167. doi: 10.1128/jvi.76.5.2159-2167.2002. PubMed DOI PMC

Look D.C., Roswit W.T., Frick A.G., Gris-Alevy Y., Dickhaus D.M., Walter M.J., Holtzman M.J. Direct suppression of Stat1 function during adenoviral infection. Immunity. 1998;9:871–880. doi: 10.1016/S1074-7613(00)80652-4. PubMed DOI

Najarro P., Traktman P., Lewis J.A. Vaccinia virus blocks gamma interferon signal transduction: Viral VH1 phosphatase reverses Stat1 activation. J. Virol. 2001;75:3185–3196. doi: 10.1128/JVI.75.7.3185-3196.2001. PubMed DOI PMC

Arbiza J., Mirazo S., Fort H. Viral quasispecies profiles as the result of the interplay of competition and cooperation. BMC Evol. Biol. 2010;10:137. doi: 10.1186/1471-2148-10-137. PubMed DOI PMC

Ojosnegros S., Perales C., Mas A., Domingo E. Quasispecies as a matter of fact: Viruses and beyond. Virus Res. 2011;162:203–215. doi: 10.1016/j.virusres.2011.09.018. PubMed DOI PMC

Lauring A.S., Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010;6:e1001005. doi: 10.1371/journal.ppat.1001005. PubMed DOI PMC

Villarreal L.P., Witzany G. Rethinking quasispecies theory: From fittest type to cooperative consortia. World J. Biol. Chem. 2013;4:79–90. doi: 10.4331/wjbc.v4.i4.79. PubMed DOI PMC

Domingo E., Perales C. Viral quasispecies. PLoS Genet. 2019;15:e1008271. doi: 10.1371/journal.pgen.1008271. PubMed DOI PMC

Huang W.T., Lin C.W. EBV-encoded miR-BART20-5p and miR-BART8 inhibitthe IFN-γ-STAT1 pathway associated with disease progression in nasal NK-cell lymphoma. Am. J. Pathol. 2014;184:1185–1197. doi: 10.1016/j.ajpath.2013.12.024. PubMed DOI

Drappier M., Michiels T. Inhibition of the OAS/RNaseL pathway by viruses. Curr. Opin. Virol. 2015;15:19–26. doi: 10.1016/j.coviro.2015.07.002. PubMed DOI PMC

Han J.Q., Townsend H.L., Jha B.K., Paranjape J.M., Silverman R.H., Barton D.J. A phylogenetically conserved RNA structure in the poliovirus open reading frame inhibits the antiviral endoribonuclease RNaseL. J. Virol. 2007;81:5561–5572. doi: 10.1128/JVI.01857-06. PubMed DOI PMC

Han J.Q., Barton D.J. Activation and evasion of the antiviral 2′-5′ oligoadenylate synthetase/ribonucleaseL pathway by hepatitis C virus mRNA. RNA. 2002;8:512–525. doi: 10.1017/S1355838202020617. PubMed DOI PMC

Min J.Y., Krug R.M. The primary function of RNA binding by the influenza a virus NS1 protein in infected cells: Inhibiting the 2′-5′ oligo(A)synthetase/RNaseL pathway. Proc. Natl. Acad. Sci. USA. 2006;103:7100–7105. doi: 10.1073/pnas.0602184103. PubMed DOI PMC

Chang H.W., Watson J.C., Jacobs B.L. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 1992;89:4825–4829. doi: 10.1073/pnas.89.11.4825. PubMed DOI PMC

Huismans H., Joklik W.K. Reovirus-coded polypeptides in infected cells: Isolation of two native monomeric polypeptides with affinity for single-stranded and double-stranded RNA, respectively. Virology. 1976;70:411–424. doi: 10.1016/0042-6822(76)90282-8. PubMed DOI

Schröder H.C., Ugarković D., Wenger R., Reuter P., Okamoto T., Müller W.E. Binding of Tat protein to TAR region of human immunodeficiency virus type 1 blocks TAR-mediated activation of (2′-5′)oligoadenylate synthetase. AIDS Res. Hum. Retrovir. 1990;6:659–672. doi: 10.1089/aid.1990.6.659. PubMed DOI

Burgess H.M., Mohr I. Cellular 5′-3′ mRNA exonuclease Xrn1 controls double-stranded RNA accumulation and anti-viral responses. Cell Host Microbe. 2015;17:332–344. doi: 10.1016/j.chom.2015.02.003. PubMed DOI PMC

Liu S.W., Katsafanas G.C., Liu R., Wyatt L.S., Moss B. Poxvirus decapping enzymes enhance virulence by preventing the accumulation of dsRNA and the induction of innate antiviral responses. Cell Host Microbe. 2015;17:320–331. doi: 10.1016/j.chom.2015.02.002. PubMed DOI PMC

Zhao L., Jha B.K., Wu A., Elliott R., Ziebuhr J., Gorbalenya A.E., Silverman R.H., Weiss S.R. Antagonism of the interferon-induced OAS-RNaseL pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe. 2012;11:607–616. doi: 10.1016/j.chom.2012.04.011. PubMed DOI PMC

Zhang R., Jha B.K., Ogden K.M., Dong B., Zhao L., Elliott R., Patton J.T., Silverman R.H., Weiss S.R. Homologous 2′,5′-phosphodiesterases from disparate RNA viruses antagonize antiviral innate immunity. Proc. Natl. Acad. Sci. USA. 2013;110:13114–13119. doi: 10.1073/pnas.1306917110. PubMed DOI PMC

Ogden K.M., Hu L., Jha B.K., Sankaran B., Weiss S.R., Silverman R.H., Patton J.T., Prasad B.V. Structural basis for 2′-5′-oligoadenylate binding and enzyme activity of aviral RNaseL antagonist. J. Virol. 2015;89:6633–6645. doi: 10.1128/JVI.00701-15. PubMed DOI PMC

Cayley P.J., Davies J.A., McCullagh K.G., Kerr I.M. Activation of the ppp(A2′p)nA system in interferon-treated, herpes simplex virus-infected cells and evidence for novel inhibitors of the ppp(A2′p)nA-dependent RNase. Eur. J. Biochem. 1984;143:165–174. doi: 10.1111/j.1432-1033.1984.tb08355.x. PubMed DOI

Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441:101–105. doi: 10.1038/nature04734. PubMed DOI

Hornung V., Ellegast J., Kim S., Brzózka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.K., Schlee M., et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science. 2006;314:994–997. doi: 10.1126/science.1132505. PubMed DOI

Peisley A., Lin C., Wu B., Orme-Johnson M., Liu M., Walz T., Hur S. Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition. Proc. Natl. Acad. Sci. USA. 2011;108:21010–21015. doi: 10.1073/pnas.1113651108. PubMed DOI PMC

Gorman J.A., Hundhausen C., Errett J.S., Stone A.E., Allenspach E.J., Ge Y., Arkatkar T., Clough C., Dai X., Khim S., et al. The A946T variant of the RNA sensor IFIH1 mediates an interferon program that limits viral infection but increases the risk for autoimmunity. Nat. Immunol. 2017;18:744–752. doi: 10.1038/ni.3766. PubMed DOI PMC

Leung D.W., Shabman R.S., Farahbakhsh M., Prins K.C., Borek D.M., Wang T., Mühlberger E., Basler C.F., Amarasinghe G.K. Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. J. Mol. Biol. 2010;399:347–357. doi: 10.1016/j.jmb.2010.04.022. PubMed DOI PMC

Ramanan P., Edwards M.R., Shabman R.S., Leung D.W., Endlich-Frazier A.C., Borek D.M., Otwinowski Z., Liu G., Huh J., Basler C.F., et al. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc. Natl. Acad. Sci. USA. 2012;109:20661–20666. doi: 10.1073/pnas.1213559109. PubMed DOI PMC

Motz C., Schuhmann K.M., Kirchhofer A., Moldt M., Witte G., Conzelmann K.K., Hopfner K.P. Paramyxovirus V proteins disrupt the fold of the RNA sensor MDA5 to inhibit antiviral signaling. Science. 2013;339:690–693. doi: 10.1126/science.1230949. PubMed DOI

Davis M.E., Wang M.K., Rennick L.J., Full F., Gableske S., Mesman A.W., Gringhuis S.I., Geijtenbeek T.B., Duprex W.P., Gack M.U. Antagonism of the phosphatase PP1 by the measles virus V protein is required for innate immune escape of MDA5. Cell Host Microbe. 2014;16:19–30. doi: 10.1016/j.chom.2014.06.007. PubMed DOI PMC

Chatterjee S., Basler C.F., Amarasinghe G.K., Leung D.W. Molecular Mechanisms of innate immune inhibition bynon-segmented negative-sense RNA viruses. J. Mol. Biol. 2016;428:3467–3482. doi: 10.1016/j.jmb.2016.07.017. PubMed DOI PMC

Zhuang T., Yi X., Chen J., Kang P., Chen X., Chen J., Cui T., Chang Y., Ye Z., Ni Q., et al. Intracellular virus sensor MDA5 exacerbates vitiligo by inducing the secretion of chemokines in keratinocytes under virus invasion. Cell Death Dis. 2020;11:453. doi: 10.1038/s41419-020-2665-z. PubMed DOI PMC

Bailey C.C., Zhong G., Huang I.C., Farzan M. IFITM-family Proteins: The cell’s first line of antiviral defense. Annu. Rev. Virol. 2014;1:261–283. doi: 10.1146/annurev-virology-031413-085537. PubMed DOI PMC

Brass A.L., Huang I.C., Benita Y., John S.P., Krishnan M.N., Feeley E.M., Ryan B.J., Weyer J.L., Vander Weyden L., Fikrig E., et al. The IFITM proteins mediate cellular resistance to influenza AH1N1 virus, West Nilevirus, and denguevirus. Cell. 2009;139:1243–1254. doi: 10.1016/j.cell.2009.12.017. PubMed DOI PMC

Huang I.C., Bailey C.C., Weyer J.L., Radoshitzky S.R., Becker M.M., Chiang J.J., Brass A.L., Ahmed A.A., Chi X., Dong L., et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011;7:e1001258. doi: 10.1371/journal.ppat.1001258. PubMed DOI PMC

Wilkins C., Woodward J., Lau D.T., Barnes A., Joyce M., McFarlane N., McKeating J.A., Tyrrell D.L., Gale M., Jr. IFITM1 is a tight junction protein that inhibit shepatitis C virus entry. Hepatology. 2013;57:461–469. doi: 10.1002/hep.26066. PubMed DOI PMC

Habjan M., Hubel P., Lacerda L., Benda C., Holze C., Eberl C.H., Mann A., Kindler E., Gil-Cruz C., Ziebuhr J., et al. Sequestration by IFIT1 impairs translation of 2′O-unmethylated capped RNA. PLoS Pathog. 2013;9:e1003663. doi: 10.1371/journal.ppat.1003663. PubMed DOI PMC

Hyde J.L., Gardner C.L., Kimura T., White J.P., Liu G., Trobaugh D.W., Huang C., Tonelli M., Paessler S., Takeda K., et al. A viral RNA structural element alters host recognition of nonself RNA. Science. 2014;343:783–787. doi: 10.1126/science.1248465. PubMed DOI PMC

Kumar P., Sweeney T.R., Skabkin M.A., Skabkina O.V., Hellen C.U., Pestova T.V. Inhibition of translation by IFIT family members is determined by their ability to interact selectively with the 5′-terminal regions of cap0-, cap1- and 5′ppp-mRNAs. Nucleic Acids Res. 2014;42:3228–3245. doi: 10.1093/nar/gkt1321. PubMed DOI PMC

Diamond M.S. IFIT1: A dual sens or and effect or molecule that detects non-2′-Omethylated viral RNA and inhibits its translation. Cytokine Growth Factor Rev. 2014;25:543–550. doi: 10.1016/j.cytogfr.2014.05.002. PubMed DOI PMC

Wang C., Pflugheber J., Sumpter R., Jr., Sodora D.L., Hui D., Sen G.C., Gale M., Jr. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol. 2003;77:3898–3912. doi: 10.1128/JVI.77.7.3898-3912.2003. PubMed DOI PMC

Pichlmair A., Lassnig C., Eberle C.A., Górna M.W., Baumann C.L., Burkard T.R., Bürckstümmer T., Stefanovic A., Krieger S., Bennett K.L., et al. IFIT1 is an antiviral protein that recognizes 5′-triphosphate RNA. Nat. Immunol. 2011;12:624–630. doi: 10.1038/ni.2048. PubMed DOI

Bouloy M., Plotch S.J., Krug R.M. Globin mRNAs are primers for the transcription of influenza viral RNA in vitro. Proc. Natl. Acad. Sci. USA. 1978;75:4886–4890. doi: 10.1073/pnas.75.10.4886. PubMed DOI PMC

Plotch S.J., Bouloy M., Ulmanen I., Krug R.M. A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell. 1981;23:847–858. doi: 10.1016/0092-8674(81)90449-9. PubMed DOI

Pyper J.M., Clements J.E., Zink M.C. The nucleolusis the site of Borna disease virus RNA transcription and replication. J. Virol. 1998;72:7697–7702. doi: 10.1128/JVI.72.9.7697-7702.1998. PubMed DOI PMC

Reynaud J.M., Kim D.Y., Atasheva S., Rasalouskaya A., White J.P., Diamond M.S., Weaver S.C., Frolova E.I., Frolov I. IFIT1 Differentially Interferes with translation and replication of alpha virus genomes and promotes induction of Type I interferon. PLoS Pathog. 2015;11:e1004863. doi: 10.1371/journal.ppat.1004863. PubMed DOI PMC

Li S., Labrecque S., Gauzzi M.C., Cuddihy A.R., Wong A.H., Pellegrini S., Matlashewski G.J., Koromilas A.E. The human papillomavirus(HPV)-18E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene. 1999;18:5727–5737. doi: 10.1038/sj.onc.1202960. PubMed DOI

Zhou C., Tuong Z.K., Frazer I.H. Papillomavirus immune evasion strategies target the infected cell and the local immune system. Front. Oncol. 2019;9:682. doi: 10.3389/fonc.2019.00682. PubMed DOI PMC

Chang Y.E., Laimins L.A. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 2000;74:4174–4182. doi: 10.1128/JVI.74.9.4174-4182.2000. PubMed DOI PMC

Hong S., Mehta K.P., Laimins L.A. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J. Virol. 2011;85:9486–9494. doi: 10.1128/JVI.05007-11. PubMed DOI PMC

Nees M., Geoghegan J.M., Hyman T., Frank S., Miller L., Woodworth C.D. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 2001;75:4283–4296. doi: 10.1128/JVI.75.9.4283-4296.2001. PubMed DOI PMC

Barnard P., McMillan N.A. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology. 1999;259:305–313. doi: 10.1006/viro.1999.9771. PubMed DOI

Barnard P., Payne E., McMillan N.A. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology. 2000;277:411–419. doi: 10.1006/viro.2000.0584. PubMed DOI

Boccardo E., Lepique A.P., Villa L.L. The role of inflammation in HPV carcinogenesis. Carcinogenesis. 2010;31:1905–1912. doi: 10.1093/carcin/bgq176. PubMed DOI

Schneider A., Papendick U., Gissmann L., DeVilliers E.M. Interferon treatment of human genital papillomavirus infection: Importance of viral type. Int. J. Cancer. 1987;40:610–614. doi: 10.1002/ijc.2910400506. PubMed DOI

Rincon-Orozco B., Halec G., Rosenberger S., Muschik D., Nindl I., Bachmann A., Ritter T.M., Dondog B., Ly R., Bosch F.X., et al. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res. 2009;69:8718–8725. doi: 10.1158/0008-5472.CAN-09-0550. PubMed DOI

Identification of novel interferon responsive protein partners of human leukocyte antigen A (HLA-A) using cross-linking mass spectrometry (CLMS) approach

Structural determinants of peptide-dependent TAP1-TAP2 transit passage targeted by viral proteins and altered by cancer-associated mutations